Chlamydia in Indian Women: Symptoms, Testing and Treatment

• Most infected women have no symptoms at all — feeling fine does not mean you are not infected.
• Chlamydia is fully curable with antibiotics: a single 1 g dose of azithromycin or 7 days of doxycycline, both under ₹200 and free at NACO clinics.
• Untreated, it can ascend to the fallopian tubes and cause pelvic inflammatory disease, tubal infertility, and ectopic pregnancy.
• A urine NAAT test is accurate and non-invasive; sexually active women under 25 and anyone with a new partner should screen even without symptoms.
• Both partners must be tested and treated together, or reinfection is likely — a diagnosis is medical, not proof of who was unfaithful.
• Free, confidential testing and treatment are available at NACO Designated STI/RTI Clinics in every district.

Chlamydia is caused by Chlamydia trachomatis, a tiny bacterium that lives inside the cells lining the cervix, urethra, rectum, throat and eyes. The genital strains (serovars D to K) cause the sexually transmitted infection this guide is about. Other strains cause trachoma (a leading cause of preventable blindness in older Indian communities) and lymphogranuloma venereum, which are separate conditions. After infection, the bacterium quietly multiplies over a one-to-three-week incubation period and either causes mild inflammation you may not notice or spreads deeper without warning.

India has no organised national chlamydia screening programme, so the numbers are incomplete — but the available data is clear that it is common. NACO surveillance and ICMR community studies have found chlamydia in roughly 3 to 8 percent of sexually active women under 30 in general settings, more in those attending STI clinics, and higher still among women being investigated for infertility or pelvic infection.

It is more common in younger women, partly because of an anatomical feature called cervical ectopy — the cervical cells the bacterium prefers are more exposed in adolescence and early adulthood, and this recedes with age. It is also seen in monogamous married women whose only partner is their husband, because he may carry it without symptoms from a past contact. So the infection turning up in a marriage is not automatic evidence of recent infidelity.

The reason chlamydia matters far more than its mild symptoms suggest is the long-term damage. Left untreated, it ascends from the cervix to the fallopian tubes in about 10 to 15 percent of women, where it can cause pelvic inflammatory disease, tubal scarring, infertility and ectopic pregnancy. Early detection and treatment prevent this entire cascade.

Chlamydia spreads through unprotected sexual contact with an infected partner. The routes are vaginal intercourse (the most common), anal intercourse (causing rectal chlamydia, often silent but transmissible), oral sex (causing throat infection, almost always symptomless), and from an infected mother to her baby during vaginal delivery. Full penetration is not strictly required if infected secretions reach a partner's mucous membranes.

What does not spread chlamydia: shared toilets, swimming pools, towels, utensils, or ordinary household contact. The bacterium cannot survive long outside the body and needs direct mucosal contact, so casual contact carries no risk.

Condoms used consistently and correctly cut chlamydia transmission by around 80 percent for vaginal and anal sex. Female condoms, available through state social marketing and many private pharmacies, give similar protection and put control with the receiving partner. Spermicides do not protect against chlamydia and can actually increase HIV risk by irritating the mucosa, so they are not part of any modern prevention plan. For the real-world numbers, see our guide to how effective condoms actually are.

Mother-to-baby spread deserves special attention here. A woman with untreated chlamydia at vaginal delivery has roughly a 50 percent chance of passing it to her baby, causing neonatal eye infection in the first two weeks and chlamydial pneumonia in the first three months. NACO's PPTCT programme mandates HIV and syphilis screening in pregnancy but does not yet include routine chlamydia testing — a gap compared with many countries that screen all pregnant women. Asking your obstetrician to add a chlamydia NAAT (about ₹1,000–₹2,500 privately, free at NACO clinics) is reasonable if you have a new partner during pregnancy, a history of STIs, or any concern.

The single most important fact about chlamydia in women is that about 70 to 80 percent have no symptoms at all. The infection produces a low-grade inflammation you simply do not feel — the cervix may look inflamed during a speculum exam, but you notice nothing. Silent carriage is the typical presentation, not the exception.

The minority who do feel something may notice mild abnormal discharge, light bleeding between periods or after sex, a mild burning when passing urine that is easily mistaken for a UTI, or mild pelvic discomfort. None of these are reliable enough to depend on.

Because of this, screening rather than waiting for symptoms is the right approach for women at risk. The CDC recommends annual chlamydia screening for all sexually active women under 25, and for older women with a new or multiple partners. India has no equivalent national programme, but the same logic applies: young sexually active women, those planning pregnancy, and those with a new partner benefit from periodic testing even when they feel perfectly well.

The same silence is true on the male side — around half of infected men also have no symptoms. So a husband can carry and pass on chlamydia without either partner knowing. This is exactly why a diagnosis in a marriage is best handled medically (both partners get tested, both get treated) rather than as an accusation.

When chlamydia does cause symptoms in women, they are usually mild and non-specific, which is part of why it gets missed. The most common is abnormal vaginal discharge — often yellowish and mucky, sometimes with a slight change in odour, but rarely the heavy discharge of other infections. Bleeding between periods or after sex is a more telling sign, because chlamydia makes the cervix inflamed and prone to bleeding on contact. A burning sensation on urination is common when the urethra is involved and is frequently treated as a urinary tract infection when the urine culture comes back negative. Mild pelvic discomfort and pain during deep intercourse can also occur. If you are unsure whether your symptoms point to an STI, a yeast infection or a UTI, our guide on normal versus abnormal discharge can help you sort it out.

The complications are the real reason chlamydia matters. The most important is pelvic inflammatory disease (PID), which develops in 10 to 15 percent of women with untreated infection when it climbs to the uterus, fallopian tubes and pelvis. PID can be acute (fever, severe pelvic pain, abnormal bleeding) or chronic and silent — and the silent form is the most dangerous, because it scars the tubes over months to years with no symptoms you would recognise. Scarred tubes lead to tubal-factor infertility and to ectopic pregnancy, where a fertilised egg implants in the damaged tube instead of the uterus — a life-threatening emergency. Read more in our guide to pelvic inflammatory disease.

Less common complications include Fitz-Hugh-Curtis syndrome (inflammation around the liver capsule, causing right-upper-abdomen pain often mistaken for gallbladder trouble), reactive arthritis (joint inflammation triggered by the infection), and a higher risk of acquiring HIV, because inflamed genital tissue is more permeable to the virus. In pregnancy, untreated chlamydia raises the risk of waters breaking early, preterm birth and low birth weight.

Whether symptoms are present or not matters far less than whether the infection is treated. Once it is in the cervix it can ascend either way, so the medical case is simple: treat every detected infection promptly, and screen for it even when you feel fine if you are at risk. Treatment costs ₹50 to ₹200; a missed infection can cost years of fertility — the asymmetry strongly favours testing early and treating fast.

The gold-standard test is the nucleic acid amplification test (NAAT), which detects chlamydial DNA or RNA and is far more sensitive than older methods. It can be run on a first-void urine sample (just as accurate for women as for men and completely non-invasive), a self-collected or clinician-collected vaginal swab, an endocervical swab taken during a speculum exam, or rectal and throat swabs where relevant. Results usually take one to three days.

Private labs such as SRL, Metropolis, Thyrocare, Dr Lal PathLabs and Apollo Diagnostics all offer chlamydia NAAT. Standalone testing costs roughly ₹800 to ₹2,500 depending on the lab and city. A combined chlamydia-plus-gonorrhoea NAAT (sensible, because the two often travel together — see gonorrhoea in women) costs about ₹1,200 to ₹3,000. A full STI panel runs ₹3,000 to ₹8,000. Home sample collection is increasingly available in metro cities, which removes the privacy barrier that stops many women from testing at all.

The free government option is a NACO-supported Designated STI/RTI Clinic (DSRC), found in every district hospital and many primary health centres. Testing and treatment, including all antibiotics, are free and confidential — no ID is required for STI services, and results are never reported to family or employers. Anonymous HIV and STI testing is also available at NACO's Integrated Counselling and Testing Centres (ICTCs).

A note on older tests you may still be offered: enzyme immunoassay (EIA) and direct fluorescent antibody (DFA) tests miss many true infections (around 60–70 percent sensitivity versus over 95 percent for NAAT) and are now considered obsolete. Antibody (serology) testing cannot tell a current infection from a past one and is not useful for diagnosis. If a lab only offers EIA or DFA, ask whether NAAT is available; if not, choose another lab.

How often to test: the CDC recommends annual screening for sexually active women under 25 and with any new partner. Women planning a baby benefit from a pre-conception STI screen including chlamydia. Women on HIV pre-exposure prophylaxis (see PrEP for women in India) should have three-monthly STI screening. For the full landscape of confidential and home testing, including step-by-step collection, see our guide to STI testing in India: cost and anonymous options.

Treating uncomplicated chlamydia is one of the success stories of modern STI medicine — it is fully curable with a short, cheap, widely available course of oral antibiotics. The two first-line options recommended by WHO, the CDC and NACO are doxycycline 100 mg twice a day for 7 days, and azithromycin 1 g as a single dose. Both cure more than 95 percent of urogenital infections.

Since its 2021 STI Treatment Guidelines, the CDC prefers doxycycline over azithromycin because it is slightly more effective, especially for rectal infection. Azithromycin's single-dose simplicity still makes it valuable when completing a seven-day course is uncertain.

Cost and availability in India: doxycycline is around ₹50 to ₹100 for the full course (sold as Doxy-1, Doxinate and many generics), and single-dose azithromycin 1 g is about ₹40 to ₹100 (Azithral, Azax and others). Both are free at NACO DSRCs, which dispense standardised colour-coded treatment kits at the point of care so that no one leaves untreated.

Special situations: in pregnancy, doxycycline is avoided because of effects on the baby's developing teeth and bones, so azithromycin 1 g single dose is preferred, with amoxicillin 500 mg three times a day for 7 days as an alternative. A test of cure (a repeat NAAT) is done three to four weeks after treatment in pregnancy. Lymphogranuloma venereum needs 21 days of doxycycline. Rectal chlamydia is best treated with doxycycline rather than azithromycin.

Avoid sex until both partners have finished treatment plus seven days — or for the single-dose azithromycin regimen, until seven days after the dose. This window is essential to stop reinfection bouncing back and forth.

Treating you is only half the job. An untreated partner will reinfect you within weeks, so partner treatment is part of the cure, not an optional extra. The CDC and WHO recognise several approaches: you tell your partners and they come in for testing and treatment; clinic staff contact them with your consent; or expedited partner therapy (EPT), where you are given an extra course of antibiotics to pass to your partner without a separate clinic visit. EPT has been shown to cut reinfection by 20 to 40 percent compared with simply advising partners to come in.

In India, EPT is not formally part of NACO guidelines and is not widely practised, partly because prescribing for someone the doctor has not seen sits awkwardly with medical regulations, and partly because the cultural setup makes handing a husband STI medication a difficult or unsafe conversation for many women. In practice, most NACO DSRCs treat any partner who walks in (free, with or without the index patient confirming the link) and encourage you to bring partners along.

How to handle the conversation depends entirely on your relationship. In a stable, respectful marriage, a direct line — “the test came back positive, so we both need treatment” — supported by your doctor usually works, and the husband cooperates. Where this context of partner conversations feels harder, our guide to consent and intimacy in Indian marriages may help you frame it.

If disclosure could trigger blame or violence, do not put your safety at risk. A clinician can help with a more neutral message (“the doctor would like you to come in for a check”), or connect you to support through a Sakhi One Stop Centre (in every district), a Special Cell for Women, or a service like Vanitha Sahayavani in Bengaluru, for safety planning first. Some DSRCs can arrange anonymous partner notification through a counsellor. If your situation involves coercion or assault, see our guide to survivor care and support in India.

Chlamydia in pregnancy carries specific risks that justify a lower threshold for testing and treatment. For the mother, it raises the chance of waters breaking early, preterm delivery, low birth weight and postpartum womb infection. For the baby, it can cause eye infection in the first two weeks (the leading global cause of newborn conjunctivitis) and pneumonia in the first one to three months. Both are treatable, but prevention is far better.

NACO's Prevention of Parent-to-Child Transmission (PPTCT) programme mandates universal HIV and syphilis screening at the first antenatal visit, and this is well implemented across India through free ICTC testing. Chlamydia is not part of mandatory PPTCT screening — a gap from international best practice. Pregnant women with risk factors (a new partner during pregnancy, a history of STIs, a partner with other partners, or symptoms of cervicitis) should ask their obstetrician to add a chlamydia NAAT, which costs about ₹1,000 to ₹2,500 privately and is free at NACO DSRCs. Some private maternity chains now include it in comprehensive antenatal packages. For the parallel HIV pathway, see HIV and pregnancy in India.

Treatment in pregnancy uses azithromycin 1 g single dose as first line (safe in all trimesters) or amoxicillin 500 mg three times a day for 7 days as an alternative. Doxycycline is avoided in pregnancy. A test-of-cure NAAT is done three to four weeks after treatment, because persistent infection at delivery has real consequences. Babies born to mothers with confirmed chlamydia should be watched for eye infection and pneumonia and treated promptly if symptoms appear — paediatricians use oral erythromycin for 14 days for confirmed newborn infection.

The reason chlamydia matters out of all proportion to its mild symptoms is the cumulative damage to fertility from infection that goes undetected. The journey from a cervical infection to scarred fallopian tubes runs over months to years and is largely silent — many women only discover it when they cannot conceive, or when they have an ectopic pregnancy. ICMR fertility-clinic studies across India consistently name chlamydia and gonorrhoea as the leading infectious causes of tubal-factor infertility.

The mechanism is straightforward. The infection ascends to the tubes in about 10 to 15 percent of untreated women, causes inflammation, and triggers healing that scars the delicate tubal lining and forms adhesions. Scarred tubes lose the ability to move an egg or embryo, and may narrow or close. A single episode of PID causes infertility in roughly 12 percent of women; two episodes raise it to about 25 percent; three or more to about 50 percent. The risk of ectopic pregnancy is several times higher after chlamydial PID.

The good news is that this entire cascade is preventable by catching and treating chlamydia early, before it has time to climb. A young woman who tests positive and completes one week of doxycycline has essentially no increased infertility risk. A woman whose infection is missed for two years faces a much harder fertility journey. This is the case for periodic screening even without symptoms — and a pre-conception STI screen (HIV, syphilis, hepatitis B, chlamydia, gonorrhoea) at ₹3,000 to ₹6,000 is one of the most cost-effective steps in reproductive medicine. If you are getting ready to start a family, our guide to trying to conceive walks through the wider checklist.

If you are already trying to conceive and test positive, the standard approach is to finish the antibiotics, test and treat your partner, wait three to four weeks for full clearance, then resume trying. Most women who treat promptly have no lasting impact. Women with a history of repeated infections or any documented PID benefit from an earlier fertility workup rather than waiting through more unsuccessful months — a tubal patency test (HSG) checks whether the tubes are open, alongside a pelvic ultrasound, hormone testing and a partner semen analysis. Where tubes are badly damaged, IVF bypasses them entirely. If you already have one child and are struggling for a second, see secondary infertility in India.

Because chlamydia is usually silent, the strongest reasons to see a doctor are about screening and risk, not just symptoms. Book a test if you are a sexually active woman under 25, have a new or more than one partner, are planning a pregnancy, or have a partner who may have other partners — even if you feel completely well.

See a doctor promptly if you notice unusual vaginal discharge, bleeding between periods or after sex, pain or burning when passing urine that does not settle, pain during sex, or lower pelvic discomfort.

Seek urgent or emergency care if you develop fever with severe pelvic pain (possible PID needing immediate treatment), or sudden one-sided lower-abdominal pain with a missed period, dizziness or fainting — these can signal an ectopic pregnancy, which is a medical emergency. If you are pregnant and have been diagnosed with or exposed to chlamydia, tell your obstetrician so testing and safe treatment can be arranged.

• WHO — Sexually transmitted infections (STIs) fact sheet)
• WHO — Guidelines for the management of symptomatic STIs
• CDC — Sexually Transmitted Infections Treatment Guidelines, 2021: Chlamydial Infections
• NACO (National AIDS Control Organisation) — STI/RTI Services and guidelines
• NHS — Chlamydia: symptoms, testing and treatment
• ACOG — How to Prevent Sexually Transmitted Infections (STIs)